

Newport, a Cortellis solution

Grow your generics or API business

Leverage unique intelligence for your generics strategy and **API suppliers**







source of intelligence.



You're likely focusing considerable resources to gather

expansion and new partners. Operate more efficiently

using Newport, a Cortellis solution, which integrates market, API and patent data in a single, integrated

and analyze data to inform strategic decisions regarding your generics portfolio, best-fit API suppliers, market



Patent intelligence including tracking of Paragraph IV patent



Newport, trusted by 85% of the world's top 20 generics companies Robust data

Gain a competitive edge using



small molecules with synthesis schemes



manufacturers & marketers





biologics with synthesis schemes



deals



Expert team



experience in the generics industry





We're no longer looking for additional analysis or monitoring tools." **Head of Assortment Planning, STADA**

tool for important decisions.

"It's an essential strategic



Quickly and accurately identify a short-list of potential portfolio candidates with just a few clicks. Select a reliable, experienced API supplier that will be a good fit for your product using a source of expertly researched, validated data.



challenges, API, market share, company and launch data

Make better decisions and drive growth



API Availability Rating, and API Manufacturing Status

Newport Constraint Date,



candidates with the greatest probability of success

your success, or visit clarivate.com/cortellis

Contact a representative to learn how Newport can support

Make data-driven decisions with speed and certainty across the drug and device development lifecycle with the Cortellis suite of life science intelligence solutions - including customized consulting and services delivered to your specific requirements.

Only Cortellis delivers the insights needed to accelerate innovation with confidence.

Access trusted intelligence integrated across the R&D lifecycle

R&D continuum



Clinical development & regulatory compliance

Portfolio strategy & business development

Generics strategy & development Data | Insights | Consulting | Services



LS354952353 / 0]



Discovery & preclinical development

including by framing or similar means, is prohibited without the prior written consent of Clarivate Analytics.